Sartorius Stedim Biotech (Sartorius Stedim Biotech) Short Percentage of Float

View and export this data going back to . Start your Free Trial

What is Sartorius Stedim Biotech Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Sartorius Stedim Biotech's Short Percentage of Float

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sartorius Stedim Biotech's Short Percentage of Float Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Short Percentage of Float falls into.

Sartorius Stedim Biotech (Sartorius Stedim Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (OTCPK:SDMHF) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

SRTOY:USA DIM:Mexico DIMp:UK 0RG8:UK DIM:France 56S1:Germany

Address

Otto-Brenner-Strasse 20, Goettingen, DEU, 37079

Website

https://www.sartorius.com

Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.